Spine BioPharma Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$385K
- Investors
-
4
Spine BioPharma General Information
Description
Developer of non-surgical therapies designed to reduce pain, restore function, and slow or stop pathological spinal disease progression. The company offers a research-focused biopharmaceutical platform with clinically oriented therapies that aim to reduce pain, restore mobility, modulate pathological processes, and broaden potential treatment indications, enabling patients suffering from degenerative disc disease and related spinal conditions to access new medical options that may improve quality of life and slow disease progression.
Contact Information
Website
www.spinebiopharma.comCorporate Office
- 505 Park Avenue
- 14th Floor
- New York, NY 10022
- United States
Corporate Office
- 505 Park Avenue
- 14th Floor
- New York, NY 10022
- United States
Spine BioPharma Timeline
Spine BioPharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 05-Jun-2026 | $385K | Completed | Clinical Trials - Phase 3 | ||
| 5. Later Stage VC (Series D) | 18-Dec-2024 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series C) | 11-Oct-2023 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC (Series B) | 23-Mar-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series A) | 15-Apr-2021 | $10M | $11.3M | Completed | Product Development | |
| 1. Seed Round | $1.32M | $1.32M | Completed | Product Development |
Spine BioPharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | 1,980,245 | $0.010000 | $3.03 | $3.03 | 1x | $3.03 | 6.1% | |
| Seed | 3,300,000 | $0.010000 | $0.4 | $0.4 | 1x | $0.4 | 10.16% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Spine BioPharma Comparisons
Industry
Financing
Details
Spine BioPharma Competitors (3)
One of Spine BioPharma’s 3 competitors is BioRestorative Therapies, a Corporation company based in Melville, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioRestorative Therapies | Corporation | Melville, NY | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY | ||||
| Biosplice Therapeutics | Private Equity-Backed | San Diego, CA |
Spine BioPharma Patents
Spine BioPharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024172859-A1 | Peptide formulations | Inactive | 17-Feb-2023 | ||
| WO-2024172860-A1 | Peptides and formulations thereof for treatment of degenerative disc disease | Inactive | 17-Feb-2023 |
Spine BioPharma Signals
Spine BioPharma Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blindspot Ventures | Venture Capital | Minority | ||
| Cercano Management | PE/Buyout | Minority | ||
| Pacira BioSciences | Corporation | Minority | ||
| Viscogliosi Bros. | PE/Buyout | Minority |
Spine BioPharma FAQs
-
When was Spine BioPharma founded?
Spine BioPharma was founded in 2015.
-
Where is Spine BioPharma headquartered?
Spine BioPharma is headquartered in New York, NY.
-
What is the size of Spine BioPharma?
Spine BioPharma has 12 total employees.
-
What industry is Spine BioPharma in?
Spine BioPharma’s primary industry is Drug Discovery.
-
Is Spine BioPharma a private or public company?
Spine BioPharma is a Private company.
-
What is Spine BioPharma’s current revenue?
The current revenue for Spine BioPharma is .
-
How much funding has Spine BioPharma raised over time?
Spine BioPharma has raised $55.5M.
-
Who are Spine BioPharma’s investors?
Blindspot Ventures, Cercano Management, Pacira BioSciences, and Viscogliosi Bros. have invested in Spine BioPharma.
-
Who are Spine BioPharma’s competitors?
BioRestorative Therapies, Brainstorm Cell Therapeutics, and Biosplice Therapeutics are competitors of Spine BioPharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process